A detailed history of Voya Investment Management LLC transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Voya Investment Management LLC holds 229,909 shares of CRNX stock, worth $11.7 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
229,909
Previous 49,258 366.74%
Holding current value
$11.7 Million
Previous $2.31 Million 346.72%
% of portfolio
0.01%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$42.12 - $51.91 $7.61 Million - $9.38 Million
180,651 Added 366.74%
229,909 $10.3 Million
Q1 2024

May 15, 2024

SELL
$34.76 - $46.81 $151,136 - $203,529
-4,348 Reduced 8.11%
49,258 $2.31 Million
Q4 2023

Feb 14, 2024

BUY
$25.62 - $37.07 $18,625 - $26,949
727 Added 1.37%
53,606 $1.91 Million
Q3 2023

Nov 14, 2023

BUY
$15.97 - $30.59 $500,994 - $959,638
31,371 Added 145.86%
52,879 $1.57 Million
Q2 2023

Aug 14, 2023

BUY
$15.73 - $23.6 $14,188 - $21,287
902 Added 4.38%
21,508 $387,000
Q3 2022

Nov 14, 2022

BUY
$18.11 - $22.37 $13,510 - $16,688
746 Added 3.76%
20,606 $405,000
Q2 2022

Aug 15, 2022

BUY
$16.49 - $27.64 $38,850 - $65,119
2,356 Added 13.46%
19,860 $370,000
Q1 2022

May 16, 2022

BUY
$17.15 - $28.31 $36,563 - $60,356
2,132 Added 13.87%
17,504 $384,000
Q4 2021

Feb 14, 2022

BUY
$19.35 - $28.41 $24,381 - $35,796
1,260 Added 8.93%
15,372 $437,000
Q2 2021

Aug 16, 2021

BUY
$15.9 - $21.15 $13,546 - $18,019
852 Added 6.43%
14,112 $266,000
Q1 2021

May 17, 2021

BUY
$13.3 - $17.55 $9,948 - $13,127
748 Added 5.98%
13,260 $203,000
Q4 2020

Feb 16, 2021

BUY
$12.08 - $17.46 $151,144 - $218,459
12,512 New
12,512 $177,000

Others Institutions Holding CRNX

About Crinetics Pharmaceuticals, Inc.


  • Ticker CRNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,752,800
  • Market Cap $2.73B
  • Description
  • Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...
More about CRNX
Track This Portfolio

Track Voya Investment Management LLC Portfolio

Follow Voya Investment Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Voya Investment Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Voya Investment Management LLC with notifications on news.